CHMP recommends approval of Ayvakyt in gastrointestinal stromal tumours.- Blueprint Medicines
The Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Ayvakyt (avapritinib), from Blueprint… read more.